Simplified Interpretation of Genomic Profiles

Smarter, Faster, Automated
Turns complex tertiary NGS reports into concise summaries, reduces manual
interpretation time and helps labs scale effortlessly.

-85%

Reduction in interpretation time

7x

Cases per FTE

3x

Test orders

Our Partners

Labor becker
Oncomedeor
Clear Spaces - ACT GENOMICS - TM Logo - Blue
Challenges

Navigating the complexities of Genomic Data Interpretation

Genomic sequencing yields vast data, but interpreting it is time-consuming, labor-intensive, and error-prone. Healthcare providers face challenges such as:

Report Complexity

80% of oncologists complain about NGS
report complexity

Scarce Ressource

Access to genomics specialists is a
crucial bottleneck

Fast Paced

There are more than >170k new publications in oncology in 2022
The Qnomx solution

AI-Powered Interpretation for Streamlined Genomic Insights

Qnomx revolutionizes genomic data interpretation by providing

Automate clinical analysis

Reduces manual effort,
saving time and costs.

Standardize
reporting

Ensures accuracy and
consistency across reports.

Boost oncologist
confidence

Delivers clear insights, increasing oncologist trust and test adoption.

Scalable
solutions

Enables labs to process more cases without additional resources.

How Qnomx Works

1

Upload Report

Upload the lab’s genomic profile
(tertiary analysis) report.

2

AI Interpretation

Our AI extracts key clinical insights through a simple, interactive interface.

3

Draft Clinical Summary

Qnomx provides a ready-to-review clinical summary in local language for lab approval.

Solutions for our audiences

Empowering Diverse
Stakeholders in Precision
Oncology

Solution for

Clinical Laboratories

Reduce manual effort, cut costs, and scale without adding staff.
Automates the interpretation process, standardizing clinical summary creation and reduces costs
7x more cases processing without additional resources
85% reduction in interpretation time
1 (1)
2 (1)

Solution for

Bioinformatics Companies

Make genomic reports clinically actionable and gain a competitive edge
Adds automated AI-driven interpretation to the tertiary analysis, making reports more actionable
Supports demand generation for NGS testing
Increases client satisfaction and retention, with more meaningful insights

Solution for

Oncology Clinics

Make genomic reports clinically actionable
Distills therapy-relevant insights, faster
Cuts down MTB preparation time, freeing up valuable clinical resources.
Keeps you updated with real-time clinical insights making decision-making faster and more precise
3 (1)

Trusted by Leading Experts

“Based on our expertise in molecular pathology and genetic testing, we see significant potential in CGC Genomics’ Qnomx platform to further optimize the interpretation of complex genomic data. This partnership allows us to increase the efficiency and quality of our NGS process and make a valuable contribution to precision medicine.“ 

Marc Becker, Managing Director of Labor Becker MVZ eGbR

Our Team

James Creeden MD, PhD
Co-Founder & Co-CEO
Joerg Hoelzing MBA, PhD
Co-Founder & Co-CEO
marcus
Marcus Olivecrona, MSc
Co-Founder & CTO
Our Mission
Advancing Precision
Oncology
We are dedicated to ensuring every cancer patient receives optimal care by providing reliable and actionable genomic insights, empowering oncologists to make informed treatment decisions.
Our Expertise
Navigating Complex
Genomic Data
With years of experience analyzing thousands of intricate cancer genomics cases worldwide, our team excels in interpreting complex genomic data, bridging the gap between raw data and clinical application.
Our Commitment
Realizing the Potential of
Genomic Medicine
We believe that the full potential of precision oncology is achieved through accurate and effective genomic data interpretation. Our mission is to provide comprehensive and precise analyses of genomic testing results, ensuring that complex data translates into meaningful patient care.

FAQs

What does Qnomx do?
Qnomx is an AI-powered platform that automates the interpretation of cancer genomic profiles. It transforms complex NGS reports into concise, clinically actionable summaries to help oncology labs and oncologists make faster, clearer treatment decisions.
What makes Qnomx different from existing bioinformatics platforms?
Bioinformatics platforms process sequencing data and generate comprehensive genomic reports as the result of the tertiary analysis. We are complementary by adding the missing step: automated interpretation of these reports into concise, actionable clinical summaries, delivered in the lab’s local language. This helps labs reduce manual workload, accelerate turnaround times, and improve the clarity of results for their clinical partners.
Can Qnomx integrate with existing lab workflows?
Yes, Qnomx is designed for fast adoption. Labs can simply upload genomic reports via a web interface or API without the need for deep integration into LIMS, EMR, or EHR systems. No data mapping or workflow overhaul required.
How does Qnomx ensure high-quality interpretations?
Qnomx uses proprietary AI models trained on curated datasets and trusted clinical sources such as ClinVar, COSMIC, NCCN, OncoKB, HGMD, GENIE, CIVIC, and peer-reviewed literature. Our clinical insights are further strengthened by over 15,000 hours of hands-on experience from our team in interpreting complex cancer genomic cases, ensuring consistent and clinically relevant outputs.
Does Qnomx cover all types of cancer?
Yes, Qnomx is cancer-agnostic and supports all metastatic cancer indications where NGS sequencing is used, helping labs and clinicians across a wide range of oncology cases.
What data does Qnomx use for the interpretation – FASTQ, VCF, or the tertiary analysis?
Qnomx starts once the tertiary analysis is completed and a finalized genomic profile report is available. We do not process FASTQ or VCF files. Instead, we interpret the completed report generated by the lab’s bioinformatics pipeline to deliver clinical summaries and treatment recommendations.

Ready to Automate Genomic Interpretation?

Join the future of precision medicine with AI-powered genomic insights.

News

Handelsblatt Article about our recent founding round
Interview with our co-founder James Creeden, MD PhD
Marcus Olivecrona joins our teams as CTO
CGC /Qnomx wins Community award at GenAI Zurich Event